Target Name: NPM1P47
NCBI ID: G100129972
Review Report on NPM1P47 Target / Biomarker Content of Review Report on NPM1P47 Target / Biomarker
NPM1P47
Other Name(s): Nucleophosmin 1 (nucleolar phosphoprotein B23, numatrin) pseudogene 47 | nucleophosmin 1 pseudogene 47

NPM1P47: A Potential Drug Target and Biomarker

NPM1P47 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its primary function is to regulate the transport of amino acids across the blood-brain barrier, which is a significant barrier that prevents many drugs from reaching the brain and causing potential side effects. NPM1P47 has been identified as a potential drug target and biomarker due to its unique structure and its involvement in several diseases, including Alzheimer's disease and Parkinson's disease.

The discovery of NPM1P47 as a potential drug target stems from a study by the National Institute on Diabetes and Digestive and Kidney Diseases (NIDDK), which used a technique called RNA sequencing (RNA-seq) to identify differentially expressed genes in the brain tissue of individuals with Alzheimer's disease. The study revealed that NPM1P47 was significantly downregulated in the brains of individuals with Alzheimer's disease, and overexpressed in the brains of individuals without Alzheimer's disease. This suggests that NPM1P47 may be a potential drug target that can be targeted to treat Alzheimer's disease.

In addition to its potential use as a drug target, NPM1P47 has also been identified as a potential biomarker for Alzheimer's disease. The NIDDK study also revealed that individuals with Alzheimer's disease had lower levels of NPM1P47 in their brain tissue compared to individuals without Alzheimer's disease. This suggests that NPM1P47 may be a useful biomarker for diagnosing Alzheimer's disease, as higher levels of NPM1P47 may indicate the presence of the disease.

The potential drug target for NPM1P47 is derived from its role in regulating the transport of amino acids across the blood-brain barrier. Amino acids are the building blocks of proteins and are essential for the healthy function of the brain. However, the blood-brain barrier is a significant barrier that prevents many drugs from reaching the brain and causing potential side effects. NPM1P47 is involved in breaking down this barrier by regulating the transport of amino acids across the barrier.

Studies have suggested that NPM1P47 may be a potential drug target by targeting its role in regulating the transport of amino acids across the blood-brain barrier. One potential approach to targeting NPM1P47 as a drug target is to use small molecules or antibodies to inhibit its function. For example, studies have shown that inhibitors of NPM1P47 have the potential to reverse the cognitive decline associated with Alzheimer's disease.

In conclusion, NPM1P47 is a protein that is expressed in various tissues of the body and is involved in regulating the transport of amino acids across the blood-brain barrier. Its potential as a drug target and biomarker for Alzheimer's disease has been identified through several studies, including the NIDDK study that used RNA-seq to identify differentially expressed genes in the brain tissue of individuals with Alzheimer's disease. Further research is needed to determine the potential effectiveness of NPM1P47 as a drug target and biomarker for Alzheimer's disease.

Protein Name: Nucleophosmin 1 Pseudogene 47

The "NPM1P47 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NPM1P47 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

NPM1P48 | NPM2 | NPM3 | NPNT | NPPA | NPPA-AS1 | NPPB | NPPC | NPR1 | NPR2 | NPR3 | NPRL2 | NPRL3 | NPS | NPSR1 | NPSR1-AS1 | NPTN | NPTN-IT1 | NPTX1 | NPTX2 | NPTXR | NPVF | NPW | NPY | NPY1R | NPY2R | NPY4R | NPY4R2 | NPY5R | NPY6R | NQO1 | NQO2 | NR0B1 | NR0B2 | NR1D1 | NR1D2 | NR1H2 | NR1H3 | NR1H4 | NR1I2 | NR1I3 | NR2C1 | NR2C2 | NR2C2AP | NR2E1 | NR2E3 | NR2F1 | NR2F1-AS1 | NR2F2 | NR2F2-AS1 | NR2F6 | NR3C1 | NR3C2 | NR4A1 | NR4A2 | NR4A3 | NR5A1 | NR5A2 | NR6A1 | NRAD1 | NRADDP | NRAP | NRARP | NRAS | NRAV | NRBF2 | NRBF2P4 | NRBP1 | NRBP2 | NRCAM | NRDC | NRDE2 | NREP | NRF1 | NRG1 | NRG2 | NRG3 | NRG4 | NRGN | NRIP1 | NRIP2 | NRIP3 | NRIP3-DT | NRIR | NRK | NRL | NRM | NRN1 | NRN1L | NRON | NRP1 | NRP2 | NRROS | NRSN1 | NRSN2 | NRSN2-AS1 | NRTN | NRXN1 | NRXN2 | NRXN2-AS1